BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 31410753)

  • 1. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
    Dong Z; Liao B; Shen W; Sui C; Yang J
    Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
    Liu Z; Li S; Zeng J; Zhou X; Li H; Liu X; Li F; Jiang B; Zhao M; Ma T
    Life Sci; 2020 Sep; 257():118068. PubMed ID: 32653521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
    Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
    Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
    Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
    Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1.
    Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
    J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M
    Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
    Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis.
    Xie Q; Wang L; Zheng S
    Dis Markers; 2020; 2020():1817931. PubMed ID: 32724483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.
    Shi RY; Yang XR; Shen QJ; Yang LX; Xu Y; Qiu SJ; Sun YF; Zhang X; Wang Z; Zhu K; Qin WX; Tang ZY; Fan J; Zhou J
    Cancer; 2013 Mar; 119(5):993-1003. PubMed ID: 23132676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
    Jin J; Ryu HS; Lee KB; Jang JJ
    PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
    Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
    Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Homer1 as a potential prognostic marker for intrahepatic cholangiocarcinoma.
    Wu SY; Yu MX; Li XG; Xu SF; Shen J; Sun Z; Zhou X; Chen XZ; Tu JC
    Asian Pac J Cancer Prev; 2014; 15(7):3299-304. PubMed ID: 24815486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in extrahepatic cholangiocarcinoma.
    Walter D; Herrmann E; Schnitzbauer AA; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S
    Histopathology; 2017 Sep; 71(3):383-392. PubMed ID: 28419539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome.
    Yang XW; Li L; Hou GJ; Yan XZ; Xu QG; Chen L; Zhang BH; Shen F
    Oncotarget; 2017 Jan; 8(5):7710-7721. PubMed ID: 28032598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.